* ESSA Pharma Inc EPIX.OQ EPIX.O is expected to show a no
change in quarterly revenue when it reports results on August 6
(estimated).
* Refinitiv's mean analyst estimate for ESSA Pharma Inc is for
a loss of 26 cents per share. For the same quarter last year,
the company reported a loss of 24 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for ESSA Pharma Inc
is $42, about 49.1% above its last closing price
of $21.38.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.21 -0.21 -0.36 Missed -68.2
Dec. 31 2020 -0.17 -0.17 -0.20 Missed -17.6
Sep. 30 2020 -0.20 -0.19 -0.13 Beat 33.3
Jun. 30 2020 -0.29 -0.29 -0.24 Beat 18.2
Mar. -0.22 -0.22 -0.45 Missed -104.5
31 2020
Dec. 31 2019 -0.17 -0.17 -0.22 Missed -25.7
Sep. 30 2019 -0.11 -0.17 -0.23 Missed -35.3
Jun. 30 2019 -0.54 -0.54 -0.52 Beat 3.7
This summary was machine generated August 6 at 02:50 GMT. All
figures in US dollars unless otherwise stated